Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Primary (de novo) glioblastomas develop in older patients and are characterized by epidermal growth factor (EGF) receptor amplification/overexpression, p16 deletion, and PTEN mutations, whereas secondary glioblastomas that progressed from low-grade or anaplastic astrocytoma develop in younger patients and frequently contain p53 mutations.
|
10666371 |
2000 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
|
14624623 |
2004 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
According to the prevailing model, NHE9 overexpression leads to an increase in plasma membrane density of epidermal growth factor receptors (EGFRs) which consequently enhances GBM cell proliferation and migration.
|
31532058 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, immunoreactivity for the EGF receptor prevailed in primary glioblastomas (63%) but was rare in secondary glioblastomas (10%).
|
8864278 |
1996 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
|
22891331 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lymphocytes were depleted in the classical transcriptional class and in EGF receptor (EGFR)-amplified and homozygous PTEN-deleted glioblastomas.
|
23864165 |
2013 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells.
|
11515790 |
2001 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, while under normoxic conditions, EGF stimulates the activation of both the PI3K and the MAPK pathways and the induction of VEGF, in glioblastoma cells, hypoxic conditions lead to the suppression of the PI3K/RhoA/C pathway and an exclusive switch to the MAPK pathway.
|
31698752 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells.
|
25053824 |
2014 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme.
|
28934307 |
2017 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
|
11454673 |
2001 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma.
|
17175377 |
2007 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.
|
16697959 |
2006 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we developed a purification strategy to directly isolate EGFR<sup>+/-</sup> populations from human germinal matrix (GM) and adult subventricular zone autopsy tissues, and from de novo glioblastoma (GBM) resections, enriching for cells capable of binding EGF ligand (<sup>LB</sup>EGFR<sup>+</sup>), and uniquely compared their functional and molecular properties.
|
28434940 |
2017 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.
|
9334810 |
1997 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion.
|
24045955 |
2013 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Heparin-binding epidermal growth factor (EGF)-like growth factor (HBEGF) is a ligand for the EGF receptor (EGFR), one of the most commonly amplified receptor tyrosine kinases (RTKs) in glioblastoma (GBM).
|
28368403 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor.
|
10576656 |
1999 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
DAB(389)EGF may have potential for intracranial therapy of EGFR-positive glioblastomas.
|
12702570 |
2003 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we report the development and selection for a rearranged amplified EGF receptor, which lacks cytoplasmic amino acid sequences in a human glioblastoma xenograft.
|
10411339 |
1999 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found 7 SNPs in haplotype 4 in EGF that were associated with prognosis in glioblastoma patients.
|
20197289 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To assess whether coselection of EGFR gains on 7p12 and monosomy 10 in glioblastomas promotes tumorigenic epidermal growth factor (EGF) signaling through loss of the annexin A7 (ANXA7) gene on 10q21.1-q21.2 and whether ANXA7 acts as a tumor suppressor gene by regulating EGFR in glioblastomas.
|
19602687 |
2009 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, glioblastomas may emerge from the microenvironmental outgrowth of more malignant clones in a complex vicious cycle that involves necrosis, hypoxia, growth factor release, angiogenesis and clonal selection; growth signals mediated by activation of epidermal growth factor receptors may precipitate glioblastomas.
|
9161727 |
1997 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Kinase-deficient erbB proteins reduced epidermal growth factor (EGF)-induced tyrosine phosphorylation of endogenous Shc proteins and also reduced immediate and sustained EGF-induced ERK MAPK activities in human glioblastoma cells, although basal ERK MAPK activities were unaffected.
|
10541432 |
1999 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A mutant epidermal growth factor (EGF) receptor missing 267 amino acids from the exoplasmic domain is common in human glioblastomas.
|
11087732 |
2001 |